January 2026: Amgen completed Phase 3 enrollment for MariTide (AMG 133) in the MARITIME-Obesity trial, with interim efficacy data expected in Q3 2026 that will position the monthly injection GLP-1/GIP antagonist as a once-monthly obesity treatment alternative
The theoretical synergies described are based on component mechanisms rather than validated combination studies
Budget-constrained individuals: If cost is a major concern, focus resources on diet, exercise, and possibly oral supplements first
Brain Primary target Nervous System Melanocortin receptor agonist affecting appetite, sexual function, and skin pigmentation pathways Frequently Asked Questions
This ratio represents the percentage of income required to maintain a full year of GLP-1 treatment, revealing where affordability challenges are most severe
Inhibition of GCH1 reduced BH4 and resulted in enhanced erastin-induced iron accumulation and lipid peroxidation, thereby enhancing ferroptosis sensitivity, while BH4 supplementation suppressed ferroptosis-related changes caused by GCH1 downregulation
